Volume XXIV No. 12 – August 28, 2017
In this issue:
THE ERROR MAY ONLY AFFECT A FEW PATIENTS, but Invitae’s failure to test for the Boland Inversion across some 50,000 patients may set a record for such an error. THE DARK REPORT broke the news of this mistake, and in this issue delivers analysis of the fallout, including the fact that Invitae’s assays are laboratory-developed tests (LDTs), which the FDA has been pushing to regulate for the past three years. Also in this issue, TDR discusses the costs for redoing genetic tests, and Invitae’s push to expand its market share.